LGT Group Foundation Buys 13,370 Shares of Edwards Lifesciences Co. (NYSE:EW)

LGT Group Foundation increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 29.6% during the 4th quarter, Holdings Channel reports. The fund owned 58,521 shares of the medical research company’s stock after acquiring an additional 13,370 shares during the period. LGT Group Foundation’s holdings in Edwards Lifesciences were worth $4,332,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Harbor Capital Advisors Inc. boosted its stake in Edwards Lifesciences by 2.5% during the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock worth $824,000 after acquiring an additional 273 shares in the last quarter. Nordea Investment Management AB lifted its stake in shares of Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after buying an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST lifted its stake in shares of Edwards Lifesciences by 6.7% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after buying an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at $3,702,000. Finally, Avanza Fonder AB bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at $4,845,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Performance

NYSE EW opened at $71.37 on Tuesday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a 50-day simple moving average of $72.58 and a 200 day simple moving average of $70.32. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market capitalization of $42.09 billion, a PE ratio of 10.24, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,555,402. This trade represents a 12.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 37,739 shares of company stock worth $2,799,104 over the last quarter. 1.29% of the stock is currently owned by company insiders.

Analyst Ratings Changes

EW has been the topic of a number of recent research reports. The Goldman Sachs Group raised their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Citigroup raised their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Truist Financial reaffirmed a “hold” rating and issued a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Piper Sandler raised their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Finally, Evercore ISI lowered their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.